English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

PET imaging at late time points after injection may allow tracer clearance from normal tissue and hence improve image contrast and detectability. 55 Co is a promising isotope with high positron yield and a long half-life suitable for imaging at delayed time points. Here, we compared the 3 radioconjugates [ 68 Ga]Ga-DOTATATE, [ 64 Cu]Cu-DOTATATE, and [ 55 Co]Co-DOTATATE by PET/CT imaging in NOD-SCID mice bearing subcutaneous somatostatin receptor-expressing AR42J tumors. Methods:  55 Co and 64 Cu were produced by the 54 Fe(d,n) 55 Co and 64 Ni(p,n) 64 Cu nuclear reactions, whereas 68 Ga was obtained from a 68 Ge/ 68 Ga generator. 55 Co and 64 Cu were labeled with DOTATATE by heating in a sodium acetate buffer and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffer, respectively. AR42J tumor-bearing mice were dynamically scanned 0-1 h after injection. For 64 Cu and 55 Co, additional imaging was also performed at late time points after 4 and 24 h. Dose calculations were based on a known biodistribution. The cumulated disintegrations in each organ were calculated by integration of a fitted exponential function to the biodistribution of each respective organ. Equivalent doses were calculated by OLINDA/EXM using the MIRD formalism. Results: Tumor uptake was rapid from 0 to 1 h after injection for all 3 radioconjugates. Normal-tissue ratios as represented by tumor-to-liver, tumor-to-kidney, and tumor-to-muscle ratios increased significantly over time, with [ 55 Co]Co-DOTATATE reaching the highest ratio of all radioconjugates. For [ 55 Co]Co-DOTATATE, the tumor-to-liver ratio increased to 65 ± 16 at 4 h and 50 ± 6 at 24 h, which were 15 ( P &lt; 0.001) and 30 ( P &lt; 0.001) times higher, respectively, than the corresponding ratios for [ 64 Cu]Cu-DOTATATE and 5 ( P &lt; 0.001) times higher than that of [ 68 Ga]Ga-DOTATATE at 1 h. Correspondingly, tumor-to-kidney and tumor-to-muscle ratios for [ 55 Co]Co-DOTATATE were 4 ( P &lt; 0.001) and 11 ( P &lt; 0.001) times higher than that of [ 64 Cu]Cu-DOTATATE at 24 h. An equivalent dose was calculated as 9.6E-02 mSv/MBq for [ 55 Co]Co-DOTATATE. Conclusion: [ 55 Co]Co-DOTATATE demonstrated superior image contrast compared with [ 64 Cu]Cu-DOTATATE and [ 68 Ga]Ga-DOTATATE for PET imaging of somatostatin receptor-expressing tumors, warranting translation into clinical trials. Dosimetry calculations found that effective doses for [ 55 Co]Co-DOTATATE were comparable to those for both [ 64 Cu]Cu-DOTATATE and [ 68 Ga]Ga-DOTATATE.

the journal of nuclear medicine

Improving Contrast and Detectability: Imaging with [55Co]Co-DOTATATE in Comparison with [64Cu]Cu-DOTATATE and [68Ga]Ga-DOTATATE